Longterm renal outcome after 10 years enzyme replacement therapy with agalsidase A in Fabry male patients

被引：0
|
作者：
Karabul, Nesrin [1 ]
Arash, Laila [1 ]
Waechter, Maike [1 ]
Beck, Michael [1 ]
Kampmann, Christof [1 ]
Mengel, Eugen [1 ]
机构：
[1] Villa Metabol, Mainz, Germany
来源：
MOLECULAR GENETICS AND METABOLISM | 2014年 / 111卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2013.12.130
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
118
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [31] Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study
    Mignani, R
    Panichi, V
    Giudicissi, A
    Taccola, D
    Boscaro, F
    Feletti, C
    Moneti, G
    Cagnoli, L
    KIDNEY INTERNATIONAL, 2004, 65 (04) : 1381 - 1385
  • [32] Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
    Mehta, A.
    Beck, M.
    Elliott, P.
    Giugliani, R.
    Linhart, A.
    Sunder-Plassmann, G.
    Schiffmann, R.
    Barbey, F.
    Ries, M.
    Clarke, J. T. R.
    LANCET, 2009, 374 (9706): : 1986 - 1996
  • [33] RENAL FOLLOW-UP BIOPSIES IN YOUNG MALE FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY
    Tondel, Camilla
    Bostad, Leif
    Svarstad, Einar
    CLINICAL THERAPEUTICS, 2010, 32 : S105 - S107
  • [34] Burden of Fabry disease in young patients (≤30 years of age) who were initiated on enzyme replacement therapy with agalsidase beta: a Fabry Registry analysis
    Hopkin, Robert J.
    Brand, Eva
    Rasmussen, Ulla F.
    Germain, Dominique P.
    Guffon, Nathalie
    Jovanovic, Ana
    Kantola, Ilkka
    Karaa, Amel
    Lemay, Roberta
    Martins, Ana M.
    Wilcox, William R.
    Yoo, Han-Wook
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S65 - S66
  • [35] The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease
    Clarke, Joe T. R.
    West, Michael L.
    Bultas, Jan
    Schiffmann, Raphael
    GENETICS IN MEDICINE, 2007, 9 (08) : 504 - 509
  • [36] Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease
    Spinelli, L
    Pisani, A
    Sabbatini, M
    Petretta, M
    Andreucci, MV
    Procaccini, D
    Lo Surdo, N
    Federico, S
    Cianciaruso, B
    CLINICAL GENETICS, 2004, 66 (02) : 158 - 165
  • [37] Neuropathologic findings in Fabry's disease patient after enzyme replacement therapy with agalsidase beta.
    Rapckwicz, A
    Abu-Asab, M
    Tsokos, M
    Schiffman, R
    Quezado, M
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2005, 64 (05): : 452 - 452
  • [38] Agalsidase alfa - a preparation for enzyme replacement therapy in Anderson-Fabry disease
    Beck, M
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) : 851 - 858
  • [39] Antiproteinuric therapy and Fabry nephropathy:: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-β
    Tahir, Hindia
    Jackson, Leslie L.
    Warnock, David G.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (09): : 2609 - 2617
  • [40] Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry
    Hopkin, Robert J.
    Cabrera, Gustavo
    Charrow, Joel
    Lemay, Roberta
    Martins, Ana Maria
    Mauer, Michael
    Ortiz, Alberto
    Patel, Manesh R.
    Sims, Katherine
    Waldek, Stephen
    Warnock, David G.
    Wilcox, William R.
    MOLECULAR GENETICS AND METABOLISM, 2016, 119 (1-2) : 151 - 159
12345